R & D

The Company continues investing into researching and treating a variety of diseases with mesenchymal stem cells and their paracrine substances. One focus will be on Neurodegenerative diseases, the largest medical, social and socio-economical challenge of our time. Preclinical and clinical trials for Alzheimer Disease, Dementia and Parkinson Disease are being prepared and registration as ATMP (advanced therapy medicinal product) as well as autologous treatments is envisaged.

In the 21st Century, live expectancy has rapidly progressed as has the number of previously uncommon diseases with no treatment. Stem Cell based therapies are able to repair and regenerate cells and tissues in diseases such as autoimmune diseases, osteoarthritis, cardiovascular hypoxia, skin and neurological diseases and stroke.

We are able to adapt treatments with the secretome of mesenchymal stem cells to different diseases as well as to individual patients.

Our ExoRAP® and ExoPAN® technology uses a protocol of pre-treatment of the cultured MSC in special media and various anoxia conditions instead of hypoxia. With this protocol a 30 fold increase in RNA content per cell can be achieved. Our knowhow is based on the right (proven & tested & validated) amount and type of media used and the perfect cultivation and production conditions.
We can alter the secretome according to the disease condition of the patient enabling disease-focused individual treatments. The secretome is devoid of all cells which decreases the risk of unwanted reactions.

Introduction to mesenchymal stem cells

Throughout our lives, adult stem cells help to maintain and regenerate our organs and tissue.
Stem cells identify damaged tissue in our body and help with the healing processes.

Previously, stem cells were obtained from umbilical cord or bone marrow, but during the last few years, fat tissue has emerged as an ideal source of adult stem cells.

Scientists all over the world agree that stem cells are the key factor in regenerative medicine, tissue repair and anti-ageing!

In the 21st century, live expectancy has rapidly progressed as has the number of previously uncommon diseases with no treatment. Stem cell based therapies are able to repair and regenerate tissues in diseases associated with age, changed life style and environmental exposure, such as autoimmune disease, osteoarthritis, cardiovascular hypoxia, skin and neurological diseases and stroke. In particular, mesenchymal stem cells (MSCs) have been applied to treat these diseases.

Mesenchymal stem cells, or MSCs, are multipotent stromal cells that can differentiate into a variety of cell types, including: osteoblasts, chondrocytes, neurons, muscle cells and adipocytes. This phenomenon has been documented in specific cells and tissues in vivo and in vitro. MSCs are distributed all over the body and are responsible for regeneration. Commonly used tissues for the isolation of MSC are bone marrow, umbilical cord, cord lining and, increasingly, adipose tissue which has a superior amount of MSCs.

In order to apply human autologous adipose tissue derived MSC (adMSC) in the clinical setting, we have developed a standardized protocol to isolate and culture-expand adMSC from minimal amounts of fat in vitro, achieving sufficient cell numbers for multiple therapeutic inventions.

Expanded adMSCs maintained the potency for effective differentiation independently of donor age and disease status. The confirmed genetic stability and in vivo safety of ex-vivo expanded adMSCs in animal models and patients indicate that even adMSC’s from older persons are applicable for autologous therapy and are comparable to those derived from young donors.

We investigated the migration ability of adMSCs and exosomes and their in-vivo homing after systemic infusion and have established several ways to let MSCs produce different kinds of secretome. We are thus able to adjust treatments with the secretome to different diseases as well as to individual patients. For instance, a simple addition of a vitamin to the stem cell culture media will augment levels of neprilysin in the secretome which then can be used to treat Alzheimer disease patients.

We are also able to transform adMSC into insulin producing cells for the replacement of beta cells of the pancreas and into dopamine producing cells to treat Parkinson disease in the near future. A large body of evidence demonstrated that MSC commonly have immunomodulatory, anti-apoptic and anti-inflammatory properties.

While the differentiation properties of MSC seem to be dependent on micro environmental clues in vivo, the immunomodulatory effects appear to be rather intrinsic and thus present an attractive basis for the therapy of autoimmune and inflammatory diseases by systemic infusion. Moreover, intrinsic properties of MSC demonstrated secretion of various factors, modulation of the local environment and activation of endogenous progenitor cells via their secretome i.e. cytokines and exosomes containing micro and messenger RNA. Hence, MSC therapy evoked therapeutic promises for graft-versus-host disease (GVHD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), diabetes, myocardial infarction, thyroditis and different types of neurological disorders, among others.

Various routes of administration of MSCs, including intravenous (i.v.), intra-arterial, intramuscular, intraarticular (i.a.) and intranasal (i.n.) were reported for stem cell application. Of these routes, i.v., i.a. and i.n. represent a convenient strategy to deliver cells and therapeutic effects to the injury site.

Initial accumulation of MSC after i.v. injection in the lungs may induce secretion of secondary anti-inflammatory effectors. The recent demonstration of in vivo homing properties of MSCs has further stimulated i.v. application of MSC for therapy.

R&D Projects / Product Development

Med Cell has international patents (pending) on the illness-focused production of stem cells and their secretome, and a promising R&D pipeline for the treatment of neurological illnesses and Diabetes at pre-clinical stage.

It intends to submit more protocols to the National Stem Cell Ethics Committee in the Bahamas and is confident that it will receive approval to treat relevant illnesses for which there is a high demand worldwide.

Med Cell enrols each patient into an observational study at clinical phase study standard and detailed data is collected. This data will potentially allow the company or third parties to skip phases I and II of a clinical trial thereby saving time and money.